High-intensity Focused Ultrasound in Treatment of Uterine Adenomyosis

checkorphan
Learn more about:
Adenomyosis
Related Clinical Trial
Factors Associated With Adenomyosis and a Clinical Scoring System for the Diagnosis Quality of Life After Hysterectomy (AdenoQOL) Low Molecular Weight Heparin on the Adenomyosis Patients’IVF-ET Outcome Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI Clinical and Molecular Study of Endometriosis and Adenomyosis Surgical Success After Laparoscopic vs Abdominal Hysterectomy Electronic Catheter Stethoscope Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Uterine Artery Embolization for Symptomatic Fibroids Oxytocin in MRI-HIFU To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Effect of Addition of Steroids on Duration of Analgesia Paracervical Block in Laparoscopic Hysterectomy Use of Dexamethasone in Uterine Artery Embolization Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Dienogest for Treatment of Adenomyotic Uteri Health-Related QoL Among Women Receiving Hysterectomy in NTUH Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis Adenomyosis and Ulipristal Acetate Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis LNG-IUS for Treatment of Dysmenorrhea Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Adenomyosis: Genomic Mechanisms and Biological Response What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Comparing Efficacy of Microwave vs Embolization Treatment for Adenomyosis Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis A Prospective Study of Diagnostic Accuracy of Ultrasound Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis A Multi-omics Study of Adenomyosis Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis Levonorgestrel Intrauterine System and Adenomyosis Validation of the Adenomyosis Calculator Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms High-intensity Focused Ultrasound in Treatment of Uterine Adenomyosis Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Norwegian Adenomyosis Study III: Peristalsis Histopathological Diagnosis of Adenomyosis Norwegian Adenomyosis Study I Vaginal Bromocriptine for Treatment of Adenomyosis Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis

Brief Title

High-intensity Focused Ultrasound in Treatment of Uterine Adenomyosis

Official Title

Therapeutic Efficacy of High-intensity Focused Ultrasound in the Treatment of Uterine Adenomyosis

Brief Summary

      Uterine adenomyosis is a common uterine benign condition. They can cause abnormal menstrual
      bleeding, and menstrual pain. Although surgical intervention is the definitive treatment,
      some women prefer to have their uterus preserved. High-intensity focused ultrasound (HIFU)
      therapy is receiving increasing interest in the management of uterine adenomyosis by inducing
      focal thermocoagulation of the fibroids. Results obtained by various research groups have
      shown that HIFU treatment is safe, effective and is highly acceptable to patients. The main
      objective of this study is to evaluate the therapeutic efficacy of HIFU in the treatment of
      uterine adenomyosis.

      In this proposed study, 10 patients who have symptomatic uterine adenomyosis who meet the
      study inclusion criteria will be invited to participate in the study which involves the use
      of HIFU in the management of the adenomyosis. Background information of the patients such as
      age, body mass index, hormonal (pre- or postmenopausal) status and the presence of chronic
      medical disease will be collected. Subjects will also be asked to complete an eight-item
      section of a Uterine Fibroid Symptom and Quality Of Life Questionnaire (UFS-QOL) and
      menstrual pain score which evaluate the effect of the adenomyosis on the quality of life of
      women.

Study Type

Interventional

Primary Outcome

Perceived symptoms change after HIFU treatment By using the menstrual pain score

Secondary Outcome

 Perceived symptoms change after HIFU treatment By using the Uterine Fibroid Symptoms Quality Of Life Questionnaire (UFS_QOL)

Condition

Adenomyosis

Intervention

HIFU treatment

Study Arms / Comparison Groups

 Treatment arm
Description:  HIFU treatment

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Procedure

Estimated Enrollment

10

Start Date

August 2016

Completion Date

June 2021

Primary Completion Date

March 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Age >40 years old, with no future childbearing plans

          -  Age >30 years old, who has tubal sterilization

          -  Significant symptoms related to adenomyosis, intractable to standard medical therapy,
             or patient considering radiological intervention (uterine fibroid embolization) or
             surgery.

          -  Clinical uterine size less than 20 weeks gestation

          -  Localized adenomyotic lesion or adenomyoma identified of less than 10 cm in diameter
             as judged by contrast MRI, involving only anterior or posterior uterine wall and not
             both.

          -  No laparotomy scars.

          -  Women should be able to give consent.

        Exclusion Criteria:

          -  Other pelvic or uncontrolled systemic diseases

          -  Confirmed or suspected pregnancy

          -  Patients who are unable to communicate with researchers during the treatment

          -  Patients who are contraindicated for MRI examination

          -  Patients with thick abdominal wall (>5 cm, as measured by MRI)

          -  Presence or history of acute pelvic inflammatory disease or any pelvic malignancy

          -  History of lower abdominal surgery, known severe pelvic endometriosis and/ or
             extensive pelvic adhesion

          -  Presence of significant sized fibroids which may interfere with the treatment or
             affect the outcome measures

Gender

Female

Ages

30 Years - 60 Years

Accepts Healthy Volunteers

No

Contacts

Vincent YT Cheung, MBBS, FRCOG, ,

Location Countries

Hong Kong

Location Countries

Hong Kong

Administrative Informations

NCT ID

NCT02954757

Organization ID

UW16-283

Responsible Party

Principal Investigator

Study Sponsor

Queen Mary Hospital, Hong Kong

Study Sponsor

Vincent YT Cheung, MBBS, FRCOG, Principal Investigator, Queen Mary Hospital, Hong Kong

Verification Date

September 2020